IncyteINCY
Market Cap: $11.8B
About: Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Employees: 2,524
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
22% more call options, than puts
Call options by funds: $51.7M | Put options by funds: $42.3M
1% more repeat investments, than reductions
Existing positions increased: 218 | Existing positions reduced: 216
0% more funds holding in top 10
Funds holding in top 10: 5 [Q1] → 5 (+0) [Q2]
0% less funds holding
Funds holding: 566 [Q1] → 565 (-1) [Q2]
1% less first-time investments, than exits
New positions opened: 73 | Existing positions closed: 74
4% less capital invested
Capital invested by funds: $12.4B [Q1] → $12B (-$445M) [Q2]
9.29% less ownership
Funds ownership: 97.08% [Q1] → 87.79% (-9.29%) [Q2]
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
9 analyst ratings
RBC Capital Brian Abrahams 52% 1-year accuracy 39 / 75 met price target | 9%upside $67 | Sector Perform Reiterated | 3 Sept 2024 |
RBC Capital Brian Abrahams 52% 1-year accuracy 39 / 75 met price target | 9%upside $67 | Sector Perform Maintained | 15 Aug 2024 |
Deutsche Bank James Shin 100% 1-year accuracy 5 / 5 met price target | 2%downside $60 | Hold Maintained | 1 Aug 2024 |
Citigroup David Lebowitz 50% 1-year accuracy 9 / 18 met price target | 44%upside $88 | Buy Maintained | 31 Jul 2024 |
JP Morgan Jessica Fye 62% 1-year accuracy 23 / 37 met price target | 0%downside $61 | Neutral Maintained | 31 Jul 2024 |
Financial journalist opinion
Based on 10 articles about INCY published over the past 30 days